Must-Watch Earnings Releases for Friday

NEW YORK ( TheStreet) -- These top five earnings releases before the weekend are all market-moving candidates.

I examine each one based on key metrics and provide an estimate on stocks I have crunched the numbers with.

MRK Chart MRK data by YCharts

Merck ( MRK)

Who They Are: Merck is a global pharmaceutical company. Its stock have an average daily trading volume of 19.1 million shares, and the company has a market capitalization of $132 billion.

52-Week High: $44.19

52-Week Low: $29.81

Float Short: 0.77%

Book Value: $18.03

Price-to-Book Ratio: 2.31

Merck is anticipated to report better second-quarter earnings before the market opens on July 27, 2012. The current consensus estimate is for earnings of $1.01 a share, an improvement of 6 cents (5.9%) from 95 cents during the same quarter last year.

More than half the analysts covering Merck rate it a buy or strong buy. Twelve of the 18 analysts covering the stock give it a buy rating, while six rate it a hold and none rate it a sell. The stock has appreciated 20% in the last year, and the average analyst target price is $44.75.

The trailing 12-month price-to-earnings ratio is 11.3. Investors are receiving $1.68 in dividends for a fat yield of 3.87%.

In the last month the stock has climbed 8%, and the shares have burned up the chart in 2012. The moving averages are in a bullish trend pattern that is just getting started. I am not a fan of Obamacare, but Merck is a winner as a result of the legislation, at least for now.

There are a couple of ways for an investor to mitigate risk going into earnings. One is to sell $44 strike call option against some or all shares owned in a covered-call strategy. I like the $45 August calls for 19 cents for an aggressive approach. The $44 strike can be sold for a more defensive posture.

If you liked this article you might like

'Date' These Potential Biotech Winners

'Date' These Potential Biotech Winners

The 10 Stocks America's Biggest Hedge Funds Are Dumping Like Crazy

Why You Keep Cash on Hand; No Downside Conviction -- Jim Cramer's Top Thoughts